Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Initial FLAG-Ida outperforms 7+3 for high-risk AML

Publish date:: February 24, 2020

Key clinical point: The FLAG-Ida regimen showed better results for high-risk patients with acute myelogenous leukemia (AML), compared with 7+3.

Major finding: The 3-year postremission overall survival was significantly better for patients receiving FLAG-Ida at 54%, compared with 39% for 7+3 treatment.

Study details: A retrospective study of 304 consecutive AML patients, with nonfavorable risk.

Disclosures: There was no outside funding for this research and the authors reported that they had no relevant financial conflicts.

Citation:

Solh MM et al. Leuk Res. 2020 Feb 14. doi: 10.1016/j.leukres.2020.106318.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,